source
- GSK to launch large trial testing shingles vaccine’s potential to reduce Alzheimer’s riskGSK announced it will conduct a large-scale clinical study to evaluate whether the shingles vaccine can lower the risk of developing Alzheimer’s disease. The move follows observations from analyses…
- GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisitionGSK announced it is ending development of camlipixant, a drug aimed at treating refractory chronic cough, after completing Phase 3 trials. The move comes as the company proceeds with its planned $…